TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23811643

Group type: EXPERIMENTAL
Intervention: 980 nm diode laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1,064 nm Nd:YAG laser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 30
Study: 20177421

Group type: EXPERIMENTAL
Intervention: p38 kinase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific enzyme inhibitors and expressed recombinant enzymes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic variation within Aox1
Number of subjects: 0
Study: 19705093

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (5 sessions over 8 weeks)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment (training program with simple gymnastic and physiotherapeutic exercises)
Number of subjects: 35
Study: 17044952

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Threshold electrical stimulation (TES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14578921

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg once daily (titrated to 20 mg if required)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Lacidipine 2 mg once daily (titrated to 4 mg if required)
Number of subjects: 222
Study: 10699342

Group type: EXPERIMENTAL
Intervention: Vaccine containing recombinant MSP2 (3D7 allele), MSP1 (190LCS.T3), and RESA antigen (C terminal 771 amino acids) in Montanide ISA 720 adjuvant, administered in two doses 6 weeks apart.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (adjuvant emulsion), administered in two doses 6 weeks apart.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups (vaccine and placebo) were challenged with approximately 140 ring infected red cells of the 3D7 cloned line, 4 weeks after the second dose.
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vaccine and placebo groups.
Number of subjects: 17
Study: 9471828

Group type: EXPERIMENTAL
Intervention: Low power laser therapy (904 nm, 5 kHz, in the dose of 1 J/cm2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Corticosteroid infiltration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of corticosteroid infiltration and laser therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Corticosteroid infiltration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (Low power laser therapy)
Number of subjects: 32
Study: 8398330

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC), 20 mg/m2 intravenously one day every 6 weeks for four courses, starting before the sixth week after surgery
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group with no further treatment after surgery
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) treatment
Number of subjects: 134
Study: 3908435

Group type: EXPERIMENTAL
Intervention: oral acyclovir 200 mg five times daily for five days
Number of subjects: 113

Group type: COMPARATOR
Intervention: matching placebo five times daily for five days
Number of subjects: 113
Study: 31937527

Group type: EXPERIMENTAL
Intervention: Health coaching for 9 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 30646130

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 2032
Study: 27568492

Group type: EXPERIMENTAL
Intervention: Percutaneous ilioinguinal nerve block with additional perineural infiltration of the ilioinguinal, iliohypogastric, genitofemoral nerves (total of 12 mL of 0.5% bupivacaine)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (Percutaneous ilioinguinal nerve block only)
Number of subjects: 92
Study: 24265189

Group type: EXPERIMENTAL
Intervention: Serial amnioinfusion
Number of subjects: 56

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 21712736

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (ET)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens + medroxyprogesterone (EPT)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Calcitriol alone
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Calcitriol + EPT/ET
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study: 16105975

Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Continued conventional chemotherapy
Number of subjects: 216
Study: 12269674

Group type: EXPERIMENTAL
Intervention: Iron plus folate (80 mg iron proteinsuccinylate + 0.370 mg folinic acid daily for 60 days)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Iron alone (80 mg iron proteinsuccinylate daily for 60 days)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Combined therapy (Iron plus folate) in the subgroup with lowest quartile of baseline haemoglobin values
Number of subjects: 371

Group type: COMPARATOR
Intervention: Iron alone in the subgroup with lowest quartile of baseline haemoglobin values
Number of subjects: 371
Study: 9696259

Group type: EXPERIMENTAL
Intervention: Scaling/root planing and polishing
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 8
Study: 7814158

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg orally 15 min before thrombolysis) + Metoprolol (i.v. not later than 1 h, then orally)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg orally 15 min before thrombolysis)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Metoprolol (not later than 1 h)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Thrombolysis only
Number of subjects: 166
Study: 2773841

Group type: EXPERIMENTAL
Intervention: Iron dextran injection at 2 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Iron dextran injection
Number of subjects: 96
Study: 319140

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline (0.01 mg/kg, maximum 0.25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous epinephrine (0.01 mg/kg, maximum 0.25 mg)
Number of subjects: 0
Study: 29466285

Group type: EXPERIMENTAL
Intervention: Brain Breaks® Physical Activity Solutions (physical activities two times per day for three to five minutes over four months)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group (no use of Brain Breaks® videos during the test period)
Number of subjects: 326
Study: 28077835

Group type: EXPERIMENTAL
Intervention: Heart health diary with guided counseling and education for 8 weeks
Number of subjects: 61
Study: 25306123

Group type: EXPERIMENTAL
Intervention: Postural audio-visual biofeedback
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Group (no biofeedback)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Study Group (biofeedback)
Number of subjects: 37
Study: 22869943

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 60
Study: 20727552

Group type: EXPERIMENTAL
Intervention: Timer watch assisted urotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard urotherapy alone
Number of subjects: 60
Study: 18280710

Group type: EXPERIMENTAL
Intervention: Risperidone (1 to 3 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 10 mg/d)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 50
Study: 16897618

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 163
Study: 12527665

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CCR) programme
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 10642384

Group type: EXPERIMENTAL
Intervention: MCT+CHO (0.36 g tricaprin (C10:0)/kg plus 0.72 g sucrose/kg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHO (0.72 g sucrose/kg)
Number of subjects: 7
Study: 8851458

Group type: EXPERIMENTAL
Intervention: Oxaprozin (1200 mg/d)
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Nabumetone (1500 mg/d)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 1510191

Group type: EXPERIMENTAL
Intervention: Oxygen therapy (50% oxygen inhalation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 25
Study: 6486489

Group type: EXPERIMENTAL
Intervention: Aminophylline (2 mg/kg intravenously) after diazepam (15 mg intravenously)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo after diazepam (15 mg intravenously)
Number of subjects: 6
Study: 31240388

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1000
Study: 28437570

Group type: EXPERIMENTAL
Intervention: Verum acupressure
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sham acupressure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 26025630

Group type: EXPERIMENTAL
Intervention: Aquatic exercise (2×60-min sessions for 8 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no aquatic exercise)
Number of subjects: 67
Study: 23532957

Group type: EXPERIMENTAL
Intervention: Training in a rectangular-shaped arena
Number of subjects: 0

Group type: COMPARATOR
Intervention: Search in the rectangular arena
Number of subjects: 0

Group type: COMPARATOR
Intervention: Search in the kite arena only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfer of search between rectangular and kite-shaped arenas
Number of subjects: 0
Study: 22947355

Group type: EXPERIMENTAL
Intervention: LCI699 (aldosterone synthase inhibitor)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 63
Study: 19655244

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at 50,000 IU weekly for 12 weeks
Number of subjects: 60
Study: 17636513

Group type: EXPERIMENTAL
Intervention: New age music
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Choice of music from one of four styles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal sounds of the operating theatre
Number of subjects: 60
Study: 16060749

Group type: EXPERIMENTAL
Intervention: Higher levels of neuroticism
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Cognitive noise
Number of subjects: 242
Study: 12134255

Group type: EXPERIMENTAL
Intervention: Amprenavir (APV) monotherapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Triple therapy (ZDV, 3TC, APV)
Number of subjects: 31
Study: 10426460

Group type: EXPERIMENTAL
Intervention: Self-esteem module (12-week program)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Regular treatment only (Control group)
Number of subjects: 95
Study: 7576390

Group type: EXPERIMENTAL
Intervention: Sucralose rinse
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucralose/maltodextrin rinse (SM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sucralose/maltodextrin/dextrose rinse (SMD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sucrose rinse
Number of subjects: 10
Study: 2274431

Group type: EXPERIMENTAL
Intervention: Thymomodulin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 46
Study: 399953

Group type: EXPERIMENTAL
Intervention: Norephedrine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 31860096

Group type: EXPERIMENTAL
Intervention: AKI outreach service (intervention hospital/area) for 20 weeks
Number of subjects: 1762

Group type: EXPERIMENTAL
Intervention: AKI outreach service (intervention hospital/area)
Number of subjects: 1762

Group type: COMPARATOR
Intervention: Control group (observational control phase)
Number of subjects: 1762
Study: 31863573

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Approach (RG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional Technique (CG)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Comparison of RG vs CG
Number of subjects: 69
Study: 31671092

Group type: EXPERIMENTAL
Intervention: Smoking heaviness (instrumented by genetic variant rs16969968) among ever smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Smoking heaviness (instrumented by genetic variant rs16969968) among never smokers
Number of subjects: 0
Study: 28703124

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg per day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Indapamide 1.5 mg per day
Number of subjects: 140
Study: 25739520

Group type: EXPERIMENTAL
Intervention: It's Your Game-Tech (IYG-Tech) program
Number of subjects: 1374

Group type: EXPERIMENTAL
Intervention: Full exposure (completion of all 13 lessons)
Number of subjects: 1374

Group type: EXPERIMENTAL
Intervention: Mid exposure (5-8 lessons)
Number of subjects: 1374
Study: 23246635

Group type: EXPERIMENTAL
Intervention: 2 mg IV buprenorphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 4 mg IV buprenorphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 8 mg IV buprenorphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 12 mg IV buprenorphine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 16 mg IV buprenorphine
Number of subjects: 5
Study: 20670096

Group type: EXPERIMENTAL
Intervention: Intranasal estradiol (300 μg/day estradiol hemihydrate)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cyclic progesterone (200 mg/day micronized progesterone for 12 days in each cycle) + Intranasal estradiol (300 μg/day estradiol hemihydrate)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 44
Study: 19204389

Group type: EXPERIMENTAL
Intervention: Test dentifrice (1,450 ppm NaF + 5% KNO3)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Reference dentifrice (1,450 ppm NaF)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo dentifrice (0 ppm F)
Number of subjects: 53
Study: 16904923

Group type: EXPERIMENTAL
Intervention: One legged knee-extension exercise for 45 minutes
Number of subjects: 18
Study: 15327190

Group type: EXPERIMENTAL
Intervention: Fosinopril (F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amlodipine (A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination therapy (F and A)
Number of subjects: 60
Study: 11269574

Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BAY 12‐9566 100 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 6
Study: 9552067

Group type: EXPERIMENTAL
Intervention: Oral granisetron 2 mg
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Intravenous ondansetron 32 mg
Number of subjects: 1054
Study: 7836534

Group type: EXPERIMENTAL
Intervention: GnRHa and steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroid replacement
Number of subjects: 0
Study: 2975554

Group type: EXPERIMENTAL
Intervention: 28 g sucrose
Number of subjects: 17

Group type: COMPARATOR
Intervention: 30 g starch and saccharin (equivalent sweetness)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: sucrose
Number of subjects: 17

Group type: COMPARATOR
Intervention: saccharin and starch
Number of subjects: 17
Study: 31433717

Group type: EXPERIMENTAL
Intervention: Medical therapy only
Number of subjects: 359
Study: 29941037

Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG), n=50
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional breathing training (control), n=50
Number of subjects: 100
Study: 27056996

Group type: EXPERIMENTAL
Intervention: S-1 (80-120 mg/day on days 1-28, followed by 14 days rest for 1 year)
Number of subjects: 961

Group type: COMPARATOR
Intervention: UFT (500-600 mg/day on days 1-5, followed by 2 days rest for 1 year)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 961

Group type: COMPARATOR
Intervention: UFT
Number of subjects: 961
Study: 24553886

Group type: EXPERIMENTAL
Intervention: Minimally invasive longitudinal approach (MILA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sinus tarsi approach (STA)
Number of subjects: 130
Study: 22382665

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (group F)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 30
Study: 20837354

Group type: EXPERIMENTAL
Intervention: EGb 761® (240 mg once daily)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 16740502

Group type: EXPERIMENTAL
Intervention: Intervention to increase fruit and vegetable consumption, physical activity, and daily multivitamin intake; decrease consumption of red meat.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention to reduce worker exposure to occupational hazards.
Number of subjects: 0
Study: 14693585

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.15 micro g/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.30 micro g/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 90
Study: 10705427

Group type: EXPERIMENTAL
Intervention: Heart failure clinic
Number of subjects: 15
Study: 9078199

Group type: EXPERIMENTAL
Intervention: Amoxycillin (750 mg three times daily for 7 days)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 214
Study: 8446850

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg single dose)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Sucralfate (1g every 6 hours)
Number of subjects: 139
Study: 3528403

Group type: EXPERIMENTAL
Intervention: MCBP (melphalan, cyclophosphamide, and carmustine in combination)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Seq‐MCBP (sequential MCBP)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: MCBPA (MCBP with doxorubicin)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: MP (IV melphalan as the only alkylating agent)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: MCBP
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: melphalan/prednisone regimen
Number of subjects: 615
Study: 3065083

Group type: EXPERIMENTAL
Intervention: Propofol infusion at a rate of 20 mg kg‐1 h‐1 for 5 min, reducing to 12 mg kg‐1 h‐1 for 10 min and then 6 mg kg‐1 h‐1 thereafter.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propofol infusion following papaveretum premedication
Number of subjects: 19
Study: 31074005

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 252

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 252
Study: 28771509

Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA for 15 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 20
Study: 25933183

Group type: EXPERIMENTAL
Intervention: DTwP-HepB+Hib vaccine (Pentavac)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Tritanrix-HB+Hib vaccine
Number of subjects: 1510
Study: 23160979

Group type: EXPERIMENTAL
Intervention: Combined TAP block and local anaesthesia
Number of subjects: 150

Group type: COMPARATOR
Intervention: Single conventional local anaesthesia
Number of subjects: 150
Study: 21667141

Group type: EXPERIMENTAL
Intervention: Alcohol-specific communication with permissive messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol-specific communication with negative alcohol messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: General parenting style and parental alcohol use
Number of subjects: 0
Study: 19234905

Group type: EXPERIMENTAL
Intervention: Unilateral pallidotomy (GPi)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Unilateral subthalamotomy (STN)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both GPi and STN groups
Number of subjects: 10
Study: 16521674

Group type: EXPERIMENTAL
Intervention: Superficial acupuncture (n=22)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Deep acupuncture (n=25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 15225149

Group type: EXPERIMENTAL
Intervention: Topiramate treatment (adjunctive)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Metabolic syndrome presence
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fasting mean total cholesterol
Number of subjects: 36
Study: 11765591

Group type: EXPERIMENTAL
Intervention: Capsicum plaster
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 9422901

Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms kg‐1
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Haemodilution
Number of subjects: 26
Study: 7684551

Group type: EXPERIMENTAL
Intervention: GH treatment (0.09U (kg BW)‐1 day‐1 sc)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 22
Study: 3101524

Group type: EXPERIMENTAL
Intervention: Ibuprofen at a dose of 2,400 mg per day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29663316

Group type: EXPERIMENTAL
Intervention: Laparoscopic lavage
Number of subjects: 83

Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 83
Study: 28490513

Group type: COMPARATOR
Intervention: Maternal and newborn supplementation with vitamin A
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Both maternal and newborn supplementation with vitamin A
Number of subjects: 1613
Study: 26245752

Group type: EXPERIMENTAL
Intervention: ARCHES intervention (brief, clinician-delivered universal education and counseling intervention)
Number of subjects: 3687

Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 3687